Glycemic control and FEV1 recovery during pulmonary exacerbations in pediatric cystic fibrosis-related diabetes

Pulmonary disease remains the most significant determinant of morbidity and mortality in cystic fibrosis (CF). Patients with CF typically experience progressive decline in lung function punctuated by pulmonary exacerbations [1], acute episodes characterized by worsened cough and sputum production and thickness, as well as decreases in pulmonary function, appetite, and weight. Over 34% of patients with CF are treated with IV antibiotics for an exacerbation each year [2]; median duration of hospitalization for these events is 9.3 days, and the median duration of IV antibiotics is 13 days [2].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research